Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study

摘要: The genes regulating circulating levels of soluble gp130 (sgp130), the antagonist inflammatory response in atherosclerosis driven by interleukin 6, are largely unknown. Aims present study were to identify genetic loci associated with sgp130 and explore potential association between variants markers subclinical atherosclerosis. is based on IMPROVE (n = 3703), a cardiovascular multicentre designed investigate determinants carotid intima media thickness, measure Genomic DNA was genotyped CardioMetaboChip ImmunoChip. About 360,842 SNPs tested for log-transformed sgp130, using linear regression adjusted age, gender, population stratification PLINK v1.07. A p value 1 × 10−5 chosen as threshold significance value. In an exploratory analysis, c-IMT measures. We identified two significantly 24 showing suggestive levels. One SNP (rs17688225) chromosome 14 positively serum (β = 0.03 SE = 0.007, p = 4.77 × 10−5) inversely (c-IMTmean–max β = −0.001 SE = 0.005, p = 0.0342). Our data indicate that multiple regulate suggest possible common pathway